← Back to Home

A New Option Before and After Bladder Cancer Surgery: FDA Approves Durvalumab Combined With an Antibody–Drug Conjugate

For patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin chemotherapy, the newly approved regimen offers a survival benefit beyond surgery alone; however, a higher rate of serious adverse events calls for careful consideration of treatment trade-offs.

By SURL BioNews

When bladder cancer has invaded the muscle layer, reducing the risk of subsequent disease beyond radical cystectomy is an important treatment consideration. For adult patients who are ineligible for or decline cisplatin chemotherapy, the U.S. Food and Drug Administration (FDA) approved a regimen spanning treatment before and after surgery on November 13, 2026: durvalumab combined with enfortumab vedotin-ejfv before surgery, followed by durvalumab monotherapy after surgery.

The regimen combines an immune checkpoint inhibitor with an antibody–drug conjugate. According to the FDA announcement and reporting by The ASCO Post, patients receive three cycles of the combination before undergoing radical cystectomy, followed by up to nine cycles of durvalumab after surgery. Surgery remains central to the overall treatment plan; the approval does not mean this approach can be used to preserve the bladder.

The VOLGA trial supporting the approval used a randomized, open-label design and assigned a total of 695 patients eligible for radical cystectomy to three groups. In addition to the newly approved regimen and surgery-alone groups, another group also received investigational tremelimumab. The 695 patients represent the total across all three groups; the key comparison underpinning this approval was the durvalumab and enfortumab vedotin regimen versus surgery alone.

The results showed that the combination regimen was superior to surgery alone in both event-free survival and overall survival. The hazard ratio for event-free survival was 0.51 (95% confidence interval, 0.38 to 0.67), and the hazard ratio for death in the overall survival analysis was 0.58 (95% confidence interval, 0.40 to 0.83). Although patients and physicians knew the treatment assignments, the primary efficacy endpoint was assessed by an independent central review blinded to those assignments.

These data demonstrate a survival advantage, but they cannot yet be translated into how much longer each patient may live. At the time of analysis, median event-free survival had not been reached in the combination regimen group, compared with 12.1 months in the surgery-alone group; median overall survival had not been reached in either group. In other words, the magnitude and duration of the long-term benefit will become clearer with continued follow-up.

Beyond efficacy, the treatment burden is also clear. Targeted Oncology reported that 71.1% of patients in the combination regimen group experienced grade 3 or higher adverse events, compared with 50.2% in the control group; grade 3 or higher events deemed treatment-related occurred in 30.7% of the combination regimen group. The first two figures include events from all causes and cannot be attributed entirely to the drugs. The FDA also lists warnings for immune-mediated adverse reactions, while common adverse reactions and laboratory abnormalities include rash, peripheral neuropathy, and elevated liver enzymes.

This approval adds a perioperative treatment option for certain patients, but VOLGA compared the regimen with surgery alone, so it cannot establish whether the regimen is superior to other drug regimens. The FDA's collaborative review with regulators in multiple countries through Project Orbis also does not mean that other regions have granted approval at the same time. In clinical practice, the next priority will be choosing an approach suited to each patient by balancing the expected survival benefit, toxicity, and the need to complete surgery.

References

  1. FDA
  2. The ASCO Post
  3. Targeted Oncology